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doRationale and Objectives: To prospectively evaluate perfusion computed tomography (CT) for assessment of changes in tumor
vascularity after chemoradiation therapy (CRT) in locally advanced rectal cancer and to analyze the correlation between baseline perfusion
parameters and tumor response.
Materials andMethods: Twenty patients with rectal cancer underwent baseline perfusion CT before CRT, and in 11 an examination after
CRT was also performed. For each tumor, blood flow (BF), blood volume (BV), mean transit time (MTT), and permeability-surface area
product (PS) were quantified. The Mann-Whitney U test compared baseline perfusion parameters of responders and nonresponders
and pre- and post-CRT measurements were compared by the Wilcoxon signed-rank test (P < .05 statistically significant for both tests).
Results: Baseline BF was significantly lower (P = .013) and MTT was significantly higher (P = .006) in responders. Both were able to
discriminate responders from nonresponders with a sensitivity of 80% and 100% and a specificity of 73.3% and 86.7%, respectively,
for BF and MTT. Baseline BV and PS were not significantly different in responders and nonresponders. Perfusion parameters changed
significantly in post-CRT scans compared to baseline: BF (P = .003), BV (P = .003), and PS (P = .008) decreased, whereas MTT increased
(P = .006).
Conclusion: Baseline BF and MTT can discriminate patients with a favorable response from those that fail to respond to CRT, potentially
selecting high-risk patients with resistant tumors that may benefit from an aggressive preoperative treatment approach.
Key Words: Computed tomography; perfusion; rectal cancer; prognosis.
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he multidisciplinary management of rectal cancer
patients has been witnessing a progressive change in
the therapeutic approach of locally advanced tumors
toward preoperative chemoradiation therapy (CRT), which
is useful for tumor downsizing and downstaging, facilitating
curative resection, decreasing the local recurrence rate, and
improving patient survival (1–7). Tumor downstaging may
lead to a partial or complete tumor regression, but in many
cases, even if the tumor cell density is significantly
decreased, the pathologic stage remains the same. The
histological tumor response to the preoperative treatment
can be assessed by the tumor regression grade (TRG),
which may be determined according to different gradingad Radiol 2011;-:1–11
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i:10.1016/j.acra.2011.10.019systems. One of them, proposed by Dworak et al, was
specifically designed for application in rectal cancer (8).
Predicting which tumors will respond well to this thera-
peutic approach remains a challenge because morphological
imaging criteria are unreliable in this regard (9–11). As it is
becoming increasingly important that preoperative imaging
may noninvasively select high-risk patients who could truly
benefit from more aggressive multimodality treatment
approaches in the preoperative setting (12,13), there is
a growing interest on functional imaging techniques that
can help monitor treatment effects. Both magnetic
resonance imaging (MRI) and computed tomography
(CT) have shown potential to act as functional biomarkers
(14–17). Perfusion CT is able to assess vascular physiology
within tumors retrieving information about tumor blood
flow (BF), blood volume (BV), mean transit time (MTT),
and vascular permeability-surface area product (PS) (18–20).
These parameters reflect vascular changes occurring in
neoplastic tissue, ultimately related to the angiogenic
process: BF reflects vascular supply to the lesion, BV reflects
functional vascular volume, MTT reflects the time of blood1
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morphology and shunting, as well as interstitial pressure, and
PS reflects leakiness of the microvasculature (21,22).
Two landmark articles have evaluated perfusion CT in the
context of rectal cancer assessment before CRT, with good
response defined as tumor downstaging (21,23), but to our
knowledge there are no published data about its use as
a biomarker for treatment monitoring using TRG as
endpoint of response to CRT. Thus the purpose of this
study was to prospectively evaluate perfusion CT to assess
tumor vascularity changes in locally advanced rectal cancer
after neoadjuvant CRT and to analyze the correlation
between baseline perfusion parameters and tumor response
to CRT, as defined by the TRG.MATERIALS AND METHODS
Patients
Between November 2007 and September 2010, 26 consecu-
tive patients met the inclusion criteria of this prospective
study, consisting of: 1) histologically (biopsy) proven non-
mucinous rectal carcinoma; 2) locally advanced disease (staged
byMRI as T3-4 and/or N positive); and 3) neoadjuvant treat-
ment consisting of long-course CRT followed by surgical
resection of the tumor. Patients with a history of allergy to
iodinated contrast agents were excluded, as were patients
locally nonresectable tumors and/or metastatic disease. These
tumors were excluded based on: 1) the assumption that it
would be impossible to foresee their downstaging and down-
sizing after CRT, thus precluding surgery within the time
frame defined in the study design, and therefore introducing
heterogeneity in the study population and 2) the fact that
metastatic tumors would not receive the same combined
CRT before an eventual surgical excision. The study received
approval from the local institutional ethical review board, and
after the procedure had been fully explained, all patients
provided written informed consent. Six patients were
excluded: two died before surgery, in three the CRT protocol
was interrupted because of complications, and one developed
metastatic disease during CRT, forcing a change in the thera-
peutic regimen. The final study population consisted of 20
patients (12 male, 8 female; median age: 57 years, range:
42–78), staged at baseline MRI as follows: T3N0 (n = 1),
T3N1 (n = 13), T3N2 (n = 5), and T4N1 (n = 1).Treatment
All patients were submitted to three-dimensional CRT with
a total dose of 5040 cGy, delivered in 180 cGy fractions, five
fractions aweek, over a period of 5.5weeks. Chemotherapeutic
agents used concomitantly during the radiotherapy were oral
capecitabine (1650 mg/m2/day, in two divided doses) or oral
tegafur-uracil (UFT) + calcium folinate (300 mg/m2/day +
90 mg/day, in three divided doses on weekdays). Surgery was
performed 6–8 weeks after completion of CRT in all patients.2CT Technique
All patients underwent baseline perfusion CT the week before
the beginning of therapy. Of these, 11 were submitted to
a second perfusion CT study within 2 weeks before surgery
(median days after baseline examination: 81; range: 74–96).
Regarding the remaining nine patients, one was unavailable
for follow-up, twowere excluded owing to technical problems
(related to peristalsis in the rectum, introducing motion
artifacts that may have interfered with the perfusion measure-
ments), and six refused the second examination. Immediately
before imaging, patients received intravenous spasmolytic
medication (1 mL of hyoscine butylbromide). Patients did
not receive oral contrast, bowel preparation, or rectal disten-
tion before the CT examinations. They were imaged in the
supine position, in a 64-section multidetector CT scanner
(Lightspeed 64, GE Healthcare Technologies, Waukesha,
WI). A preliminary nonenhanced scan of the pelvic region
(2.5-mm section thickness) was performed to localize the
tumor. Then, a board-certified radiologist (with 8 years of
experience in gastrointestinal imaging) selected a 40-mm
scanning range for dynamic CT, chosen to include the
maximum area of visible tumor.Dynamic studyof the imaging
volume, with an acquisition in cine mode, was performed
as follows: eight contiguous 2.5-mm reconstructed sections
obtained at the same table position, 1-second gantry rotation
time, 120 kVp, 300 mA. Scanning was started 5 seconds
after intravenous injection of 100 mL of nonionic iodinated
contrast agent (370 mg of iodine/mL), followed by 40 mL
of saline solution, via a pump injector at a fixed rate of
4–5mL/second through a 18–20-G catheter in the antecubital
vein. A set of eight images per second during 60 seconds was
obtained, corresponding to a total of 480 images.
Image and Data Analysis
The image datasets were transferred to an image-processing
workstation (Advantage Windows 4.3, GE Healthcare Tech-
nologies). Commercially available software (CT Perfusion
3.0, GEHealthcare Technologies) was used to calculate perfu-
sion parameters. This software uses a deconvolution algorithm
and is based on a mathematical model (24) that describes the
distribution of iodinated contrast material in tissue. Assump-
tions made within the model (23,25) include the following:
the extracapillary interstitial space is a well-mixed and
uniform compartment, and by considering the interstitial
space as a well-stirred compartment, the concentration of
solute within this space is a function of time. An adiabatic
approximation of the mathematical model (26) is used in the
perfusion software to yield perfusion parameters for a tissue
region of interest (ROI). These parameters result from
time-contrast enhancement curves of the tissue ROI and
the tissue ROI’s arterial input. Thus, the resultant perfusion
parameters represent mean values for the tissue ROI over
the period of the time-contrast enhancement curves.
CT perfusion analysis was independently performed by
a board-certified radiologist (with 4 years of experience in
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experience in perfusion CT), both blinded to each other’s
measurements, the pathology results, and the patient’s clinical
response to treatment. The arterial input was obtained by
drawing a circular ROI (maximum of 10 pixels) placed in
the external iliac artery. An arterial enhancement time curve
was automatically generated as well as functional parametric
maps, representing in a color scale pixel values of the following
perfusion parameters: BF (in milliliters per 100 g of wet tissue
per minute), BV (in milliliters per 100 g of wet tissue), MTT
(in seconds), and PS (in milliliters per 100 g of wet tissue per
minute). To quantify the baseline perfusion parameters of
a neoplasm, a free-hand ROI encompassing as much of the
tumor area as possible (pre-CRT area range: 292–1355 mm2;
post-CRT area range: 193–1099 mm2) was drawn along the
visible margins of the lesion at a single table position (where
the solid tumor areawas largest) and then automatically copied
to each functional map (Fig 1). For patients without visible
tumor burden after CRT, a ROI was placed over the rectal
wall, in the former location of the neoplasm. This method-
ology was chosen because a previous work demonstrated
that even if no residual tumor burden is visiblemacroscopically,
viable tumor cells persist in the tumor bed in up to 50% of the
cases (27). The variation rate of each perfusion parameter after
CRTwas calculated as follows: ([pre-CRTvalue] – [post-CRT
value])  100/(pre-CRT value).Standard of Reference
For the histological examination of the surgical specimen, its
circumferential resection plane was inked, and it was opened
anteriorly and fixed in formalin for 24 hours. Thewhole spec-
imen was then sectioned transversely, every 0.3 cm. The
extent of lateral spread in the mesorectum was assessed on
each slice, and the shortest distance between the tumor or
lymph node and the circumferential resection plane was
measured. Specimens were assessed by a semiquantitative
determination of the TRG as proposed by Dworak et al (8)
as the standard of reference. According to the proposed
grading system, the tumor response to CRTwas defined as
follows: grade 0, no regression; grade 1, dominant tumor
mass with obvious fibrosis and/or vasculopathy; grade 2,
dominantly fibrotic changes with few tumor cells or groups
(easy to find); grade 3, very few (difficult to find microscopi-
cally) tumor cells in fibrotic tissue with or without mucous
substance; and grade 4, no tumor cells, only fibrotic mass (total
regression or response). Tumor response after CRTwas based
on the presence of gross residual tumor: tumors with TRG
0-2 scoring were non-responders, whereas neoplasms with
TRG 3-4 scores were considered responders.Statistical Analysis
Statistical analyses were performed using the Statistical Package
for the Social Sciences (SPSS, version 17.0, Inc., Chicago, IL).
Interobserver variability between measurements of the tworeaders for pre- and post-CRT perfusion parameters was
analyzed by calculating the intraclass correlation coefficient
(ICC) (0–0.20, poor correlation; 0.21–0.40, fair correlation;
0.41–0.60, moderate correlation; 0.61–0.80, good correlation;
and 0.81–1.00, excellent correlation). Values of perfusion
parameters were averaged between the two observers for
further analysis. Because most data were not normally distrib-
uted, nonparametric tests were used. The median BF, BV,
MTT, and PS on pre- and post-CRT examinations were
compared by means of theWilcoxon signed-rank test to inves-
tigate changes in the perfusion parameters after CRT. The
Mann-Whitney U test was used to compare the variation rates
in the perfusion parameters after CRT in responders and
nonresponders and also to compare baseline ROI areas and
median BF, BV, MTT, and PS of responders and nonre-
sponders. For all of these analyses, a two-tailed P value of less
than .05 was considered statistically significant. Receiver oper-
ator characteristics (ROC) curves were generated to evaluate
the diagnostic performance for baseline perfusion parameters
in detecting a favorable response (TRG 3-4). Corresponding
areas under theROCcurve (AUC), sensitivity, specificity, posi-
tive and negative predictive values (PPV,NPV)were calculated.
For these analyses, cutoff values were determined according to
the point nearest to the upper left corner in the ROC curves.RESULTS
Treatment Characteristics
According to the abovementioned protocols, 10 patients were
treated with capecitabine, whereas UFT was given to the
remaining 10. Surgery consisted of low anterior resection
(n = 15), abdominoperineal resection (n = 4), or extended
resection (n = 1). The median interval between the baseline
perfusion scan and surgery was 101 days (range, 73–112).Histopathological Findings
After histological analysis of the surgical specimens and appli-
cation of the Dworak scoring system there were 15 nonre-
sponders (two patients with TRG 0, four patients with
TRG 1, and nine patients with TRG 2) and 5 responders
(three patients with TRG 3 and two patients with TRG 4).
Regarding pathological staging, the results showed 2 patients
with a ypT0N0, 1 a ypT1N0, 10 a ypT2N0, 4 a ypT3N0, 1 a
ypT3N1, 1 a ypT3N2, and 1 a ypT4N1 tumor.Interobserver Variability
The correlation between pre-CRT measurements of both
readers was excellent, with ICCs of 0.86 (0.67–0.94), 0.83
(0.62–0.93), 0.92 (0.80–0.97), and 0.95 (0.87–0.98), respec-
tively for the BF, BV, MTT, and PS. As for post-CRT
measurements, the correlation was good to excellent,
with ICCs of 0.77 (0.32–0.94), 0.74 (0.51–0.88), 0.89
(0.63–0.97), and 0.75 (0.52–0.84), respectively, for the same3
Figure 1. (a) Hand-drawn regions of interest (ROIs) along the visible margins of the tumor on axial images. (b) A time-enhancement curve
corresponding to the tumor ROI is also generated. Perfusion parameters are computed and values can be presented in a table or in each
one of the functional parametric maps: (c) blood flow (BF); (d) blood volume (BV); (e) mean transit time (MTT); (f) permeability-surface area
product (PS).
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ences between readers were the following: for BF, difference
on pre-CRT images was 3.75 mL/100 g/minute and on
post-CRT CT was 1.45 mL/100 g/minute; for pre-CRT
BV was 0.10 mL/100 g and on post-CRT CT was
0.33 mL/100 g; for MTTon pre-CRT scans was 0.55 seconds
and on post-CRT images was 1.70 seconds; for pre-CRT PS
was 0.95 mL/100 g/minute and for post-CRTexaminations
was 1.01 mL/100 g/minute.
ROI Areas
The median baseline ROI area was not significantly different
between tumors that responded well (495 mm2; range, 344–
723 mm2) and poorly responding lesions (625 mm2; range,
292–1355 mm2) (P = .257).
Perfusion Parameters for Assessment of Response
Differences between medians of baseline perfusion parameters
across all levels of TRG and in responders and nonresponders
are summarized in Table 1. BF was significantly lower and4MTT was significantly higher in responders than in nonre-
sponders. No significant difference was found for BV and PS
of responders and nonresponders. The AUCs for the perfusion
parameters were the following: 0.88 for BF, 0.67 for BV, 0.92
for MTT, and 0.63 for PS (Fig 2). Corresponding sensitivities,
specificities, PPV, and NPV for each perfusion parameter are
provided in Table 2. Figure 3 shows box-and-whisker plots
for BF and MTT, with depiction of the threshold value for
discrimination between responders and nonresponders. A
combination of these two perfusion parameters yielded a sensi-
tivity of 80% (95% CI, 28–99) and a specificity of 66.7% (95%
CI, 38–88) for characterization of response.Perfusion Parameters before and after CRT
In the 11 patients who underwent pre- and post-CRT perfu-
sion CT, the median BF on pre-CRT images was 61.00 mL/
100 g/minute (range, 20.10–86.60) and on post-CRTCTwas
20.10 mL/100 g/minute (range, 7.73–60.80) (P = .003). For
pre-CRT median BV was 4.84 mL/100 g (range, 3.05–5.23)
versus 2.80 mL/100 g (range, 1.64–4.26) for post-CRT CT
TABLE 1. Baseline Perfusion Parameters Across All Levels of TRG and in Responders and Nonresponders to Combined
Chemoradiation Therapy
TRG BF (mL/100 g/minute) BV (mL/100 g) MTT (s) PS (mL/100 g/minute)
Nonresponders (n = 15) 0 94.50 (50.00–139.00) 5.63 (4.65–6.60) 8.09 (4.28–11.90) 6.59 (6.57–6.61)
1 82.95 (68.00–109.00) 4.85 (4.21–5.92) 5.11 (4.88–5.62) 12.10 (10.70–18.00)
2 63.70 (41.10–118.00) 5.05 (3.05–9.14) 8.33 (5.72–11.50) 12.50 (6.36–41.40)
Total 68.00 (41.10–139.00) 5.00 (3.05–9.14) 6.82 (4.28–11.90) 11.40 (6.36–41.40)
Responders (n = 5) 3 38.60 (25.00–58.00) 4.65 (3.58–4.76) 11.10 (10.20–22.50) 13.70 (4.70–20.30)
4 40.55 (20.10–61.00) 4.73 (4.28–5.17) 15.65 (11.40–20.90) 14.80 (11.90–17.70)
Total 38.60 (20.10–61.00) 4.65 (3.58–5.17) 11.10 (10.20–22.50) 13.70 (4.70–20.30)
P value (nonresponders vs. responders) 0.013 0.256 0.006 0.407
BF, blood flow; BV, blood volume; MTT, mean transit time; PS, permeability-surface area product; TRG, tumor regression grade.
Minimum and maximum values are provided between parentheses.
TABLE 2. Diagnostic Performance of Baseline Perfusion Measurements in Detecting a Good Response to CRT
Perfusion
Parameters Sensitivity Specificity PPV NPV Cutoff Point
BF 80.0% [4/5] (28–99) 73.3% [11/15] (44–92) 50.0% [4/8] (15–84) 91.7% [11/12] (61–99) 59.25 mL/100 g/minute
BV 80.0% [4/5] (28–99) 66.7% [10/15] (38–88) 44.4% [4/9] (13–78) 90.9% [10/11] (58–99) 4.80 mL/100 g
MTT 100% [5/5] (47–100) 86.7% [13/15] (59–98) 71,4% [5/7] (29–96) 100% [13/13] (75–100) 9.52 seconds
PS 60.0% [3/5] (14–94) 80.0% [12/15] (51–95) 50.0% [3/6] (11–88) 85.7% [12/14] (57–98) 13.45 mL/100 g/minute
BF, blood flow; BV, blood volume; MTT, mean transit time; NPV, negative predictive value; PPV, positive predictive value; PS, permeability-
surface area product.
Absolute numbers are given between brackets and 95% confidence intervals are provided between parentheses. Cutoff values were chosen
according to the point nearest to the upper left corner in the receiver operating characteristic curves.
Figure 2. Comparison of receiver oper-
ating characteristic curves displaying the
diagnostic performance for baseline
measurements: (a) blood flow (BF); (b)
blood volume (BV); (c) mean transit time
(MTT); (d) permeability-surface area
product (PS) in the evaluation of good
response to chemoradiation therapy
(tumor regression grades 3 and 4). AUC,
area under the curve.
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8.63 seconds (range, 4.88–22.50) and on post-CRT images
was 15.90 seconds (range, 4.48–26.70) (P = .006). For pre-
CRT CT, median PS was 12.80 mL/100 g/minute (range,
8.55–20.30) versus 9.51 mL/100 g/minute (range, 3.71–13.50) for post-CRT examination (P = .008). Of these
11 patients, 4 were responders and 7 were nonresponders.
All responders and four nonresponders showed lower BF,
BV and PS and a higher MTT after CRT (Fig 4). Among
nonresponders, one showed higher BF and BV (Fig 5), in5
Figure 3. Box-and-whisker plots
showing baseline blood flow (BF) and
mean transit time (MTT) values of
responders (tumor regression grade
[TRG] 3-4) and nonresponders (TRG 0-2).
Boxes stretch from lower quartile to upper
quartile (25th to 75th percentile); median is
shown as a line across each bar; whiskers
show sample minimum and maximum; O
denotes outliers; red horizontal lines repre-
sent thresholds. Using a threshold value of
59.25mL/100 g/minute for BF it is possible
to differentiate responders from nonre-
sponders with a sensitivity of 80.0% and
a specificity of 73.3%. Regarding MTT,
a threshold of 9.52 seconds allows distinc-
tion between responders and nonre-
sponders with a sensitivity of 100% and
a specificity of 86.7%.
Figure 4. Good responder to chemoradiation therapy (CRT): apart from morphological changes between pre- (a) and posttherapy (d) with
a clear lesion downsizing, perfusion computed tomography showed a decrease in blood flow (BF) from pretreatment study (b) to posttreatment
examination (e). There is also an increase in mean transit time (MTT): (c) baseline; (f) post-CRT. The blood volume and the permeability-surface
area product (data and parametric maps not shown) also decreased.
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Figure 5. Poor responder to chemoradiation: absence of response to treatment was found with a lack of significant downsizing of the tumor
between pre- (a) and posttherapy (d) images. Perfusion measurements revealed a decrease in the blood flow (BF): (b) baseline; (e) post-
chemoradiation therapy (CRT), and also in the mean transit time (MTT): (c) baseline; (f) post-CRT. The blood volume and the permeability-
surface area product (data and parametric maps not shown) also decreased.
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after CRT. Nevertheless, the median variation rates of the
perfusion parameters after CRT were not significantly
different in responders and nonresponders: 58.0% versus
63.0% (P = .85) for BF, 29.1% versus 42.2% (P = .70) for
BV, 48.3% versus 84.2% (P = .70) for MTT, and 47.7% vs.
23.9% (P = .13) for PS.
Table 3 yields a detailed view of the perfusion measure-
ments on a patient-by-patient basis.
Radiation Dose
The effective radiation dose to the patients ranged from
36.03 mSv to 36.13 mSv. Of this, the cine acquisition was
responsible for 20.74 mSv, whereas the remaining effective
dose was related to the nonenhanced scans.DISCUSSION
The results of our study show that baseline BF and MTTwere
significantly different in responders and nonresponders (BFwas significantly lower and MTT significantly higher in
responders) and were accurate for predicting a favorable
tumor response to CRT, with an AUC of 0.88 and 0.92,
respectively. Baseline BV and PS were not significantly
different among responders and nonresponders. Comparing
the functional perfusion data at baseline with those obtained
following CRT conclusion, there was a significant change
in all perfusion parameters: BF, BV, and PS decreased, whereas
the MTT increased, but these changes were not different in
responders and nonresponders.
To our knowledge, assessing response to CRTas defined by
the TRG has not been focused in previous studies of perfusion
CT of rectal cancer. Former works addressed the diagnostic
value of perfusion CT in evaluating response based on
morphologic criteria of tumor downstaging (21,23). The
use of these criteria as endpoint of response to CRT may be
prone to under- or overstaging and requires accurate
baseline and post-CRT imaging examinations. However,
our study assessed response to CRT based on the TRG, which
is an objective criterion as standard of reference to evaluate7
TABLE 3. Perfusion Measurements on a Patient-by-patient Basis
Patient Number
BF (mL/100 g/mm2) BV (mL/100 g) MTT (seconds) PS (mL/100 g/mm2)
TRGPre-CRT Post-CRT Pre-CRT Post-CRT Pre-CRT Post-CRT Pre-CRT Post-CRT
1 86.60 20.20 4.86 2.00 4.88 13.00 18.00 13.50 1
2 84.80 23.60 5.08 1.85 6.15 11.00 8.55 8.99 2
3 38.60 18.40 4.65 3.21 11.10 21.00 20.30 7.89 3
4 51.30 19.00 5.23 2.24 8.63 16.00 12.50 9.51 2
5 41.10 60.80 3.05 3.38 8.80 9.70 10.90 7.20 2
6 65.20 9.22 5.05 3.05 8.33 27.00 16.60 11.10 2
7 79.30 52.90 4.84 2.80 5.62 4.50 12.80 11.90 1
8 25.00 9.08 3.58 2.61 22.50 24.00 13.70 9.00 3
9 68.00 53.00 4.21 3.50 5.19 9.90 11.40 11.10 1
10 20.10 20.10 4.28 4.26 20.90 23.00 11.90 11.80 4
11 47.80 NA 3.75 NA 8.83 NA 41.40 NA 2
12 79.70 NA 5.00 NA 6.82 NA 13.20 NA 2
13 60.50 NA 4.18 NA 7.24 NA 12.50 NA 2
14 118.00 NA 9.14 NA 5.72 NA 6.36 NA 2
15 109.00 NA 5.92 NA 5.02 NA 10.70 NA 1
16 50.00 NA 4.65 NA 11.90 NA 6.57 NA 0
17 139.00 NA 6.60 NA 4.28 NA 6.61 NA 0
18 58.00 NA 4.76 NA 10.20 NA 4.70 NA 3
19 63.70 NA 5.27 NA 11.50 NA 7.62 NA 2
20 61.00 7.73 5.17 1.64 10.40 20.00 17.70 3.71 4
BF, blood flow; BV, blood volume; CRT, chemoradiation therapy; MTT, mean transit time; NA, not applicable; PS, permeability-surface area
product; TRG, tumor regression grade.
CURVO-SEMEDO ET AL Academic Radiology, Vol-, No-,- 2011response. Moreover, grade analysis is a better predictor of
outcome after treatment than T downstaging (28). In patients
with gross residual tumor (TRG 0-2), the risk of local and
distant recurrence is increased and the disease-free survival is
statistically poor (29).
Confirming the findings of a previous study (23), our
results showed that baseline BF and MTT are different
between responders and nonresponders, being respectively
significantly higher and significantly lower in poorly respond-
ing patients. This can be theoretically explained by the pres-
ence of intratumoral arteriovenous shunts with a high
perfusion rate and low exchange of oxygen (30). Such arterio-
venous shunts were shown to account for up to 30% of total
tumor flow of blood (31–33) and in an animal study it was
demonstrated that tumoral areas of high BF in perfusion CT
images corresponded to sites of shunting of blood flow (20).
These shunts have low resistance to flow, resulting in increased
BF and shorter MTT. BV, although not significantly different,
is also higher in poor responders. It seems therefore logical
that high perfusion values, which suggest a high rate of angio-
genesis within the tumor, may point toward a poor therapy
response and/or a worse prognosis. High perfusion could
also be a result of intrinsic high angiogenic activity of tumor
(34). Interestingly, our results disagree with those from
a previous study that showed baseline BF and BV in poor
responders to be significantly lower and MTT significantly
higher than in responders (21). Reasons for these discrep-
ancies with our results may reflect the use of a different end
point to assess response, different patient selection criteria
(we did not use endorectal ultrasound for initial staging) and8also differences in the perfusion technique: a shorter scanning
time (effective scan duration of about 30 seconds) may be too
short to reliably assess PS (35,36), and the use of thicker
sections of 10 mm may also influence quantitative perfusion
data (21). Table 4 provides a comparison between the methods
and findings of our study and those from the two above
mentioned works.
Both baseline BF and MTT showed respectively AUCs of
0.88 and 0.92 in determining a good response to CRT, thus
being able to yield a diagnostically useful threshold value.
Therefore, BF values below 59.25 mL/100 g/minute
and MTT values over 9.52 seconds were found to have high
accuracy for predicting a good response to CRT. Contrarily,
baseline BV and PS could not accurately discriminate
responders from nonresponders. Again, explanation
for poor response is probably related to the opening of a signif-
icant number of arteriovenous shunts rather than the acquisi-
tion of a new vascular supply. Shunting facilitates the passage
of blood directly from the arterial to the venous beds bypassing
the exchange capillaries, hence decreasing MTT (37). This
would result in a high perfusion rate with minimal or null
exchange of nutrients (including oxygen), therefore prevent-
ing and limiting the action of chemotherapeutic drugs over
the capillary bed, helping to explain an unfavorable response
(38). We are aware, however, that this explanation, which is
also based on findings from previous reports (20,23,31–
33,38) is speculative, because it lacks pathologic confirmation.
The previous studies on perfusion CT for monitoring CRT
effects in rectal cancer showed significant changes in perfusion
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et al showed a significantly lower BF, BV, and PS after CRT
(21). In agreement with those results, we demonstrated
a significant change in perfusion parameters after CRT
compared with the baseline scan: BF, BV, and PS diminished,
whereas MTT increased. This may reflect a decreased number
of arteriovenous shunts (BF), a reduced volume of the vascular
bed (BV) and a reduced leakage from neoplastic vessels (PS).
The higher MTT is probably an expression of the sum of
changes in the tumor vascular bed itself. However, the median
variation rates of the perfusion parameters after CRTwere not
significantly different in responders and nonresponders.
Therefore, our results suggest that a baseline perfusion study
alone could discriminate between responders and nonre-
sponders and a post-CRT is not warranted in order to achieve
that goal.
Our study has limitations. Results are based on a small
patient cohort of a single center and are therefore specific to
the methods and software we used, and as such our thresholds
may not necessarily apply to other patients. They should be
regarded as preliminary data that may stimulate studies on
larger populations, especially multicenter trials encompassing
standardization of protocols for perfusion CT in this clinical
setting.
The use of a large (100 mL) dose of iodinated contrast is not
recommended by some authors, who suggest that a smaller
(<50 mL) bolus should be administered instead. Nevertheless,
it was demonstrated that contrast volumes similar to those
applied in clinical practice for abdominopelvic CT imaging
are not detrimental to the accuracy of quantitative tumor
vascular parameters measured at perfusion CT, with the
advantage of obtaining simultaneously morphological
(staging) data (39). Restrictions on the administration rates
by the caliber of the intravenous cannula usually sited in clin-
ical practice imply that rates above 5 mL/second are not
commonly used (39). Moreover, the deconvolution method
we applied can tolerate lower injection rates, such as less
than 5 mL/second (19). The free-hand drawing of a ROI in
a single slice may not fully represent the overall tumor vascular
profile and implicates a subjective judgment by the readers of
where the tumor margin is located. Therefore, even subtle
variations in ROI size and positioning between readers may
result in substantial variations in perfusion parameters.
However, observer variability is lower for this type of ROI
analysis as shown in other studies (40,41) and in
concordance with our results with good to excellent
interobserver agreement. We did not test reproducibility
because of the radiation burden and concerns of contrast-
induced nephropathy. A potentially distinct efficacy of the
different chemotherapeutic drugs with impact on the results
should theoretically be considered. We did not assess baseline
tumor volume, which may predict response to therapy (42),
nor did we evaluate changes in tumor volume after therapy,
because contrast-enhanced scans of the whole pelvis were
not performed. A direct correlation with histological markers
of angiogenesis, such as microvessel density, was not assessed9
CURVO-SEMEDO ET AL Academic Radiology, Vol-, No-,- 2011because it is not routinely performed in our institution.
Furthermore, there are limitations in its routine use as
a biomarker: it requires invasive tissue sampling, needs stan-
dardization, and suffers from random sampling errors because
the entire tumor volume is not examined, which can hamper
evaluation because of the heterogeneity of malignant
neoplasms (43).
In conclusion, baseline BF was significantly lower and
MTT was significantly higher in responders than in nonre-
sponders; both parameters can accurately discriminate patients
with a favorable response from the ones that fail to respond to
preoperative CRT, potentially selecting high-risk patients
with radio- and chemo-resistant tumors that may benefit
from a more aggressive preoperative treatment approach.ACKNOWLEDGMENTS
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